We are committed to bringing forth new treatment options for patients with acute myeloid leukemia (AML) and myclodysplastic syndrome (MDS) and have advanced a comprehensive development program with novel bispecific approaches as well as other novel targets with transformational potential.
Acute myeloid leukemia (AML) has a five year overall survival rate of only ~30%.
Acute myeloid leukemia (AML) is a disease of the bone marrow that can quickly spread to the blood. Our focus is to better understand existing standard treatment and to research new ways to overcome resistance.
Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce enough healthy blood cells, leading to anemia and the need for blood transfusions.
Types of myeloid malignancies
Acute Myeloid Leukemia (AML) by the numbers
- Five year overall survival rate of only ~30%
- Most common type of acute leukemia in adults
- Resistant to several standard therapies; patients often relapse with poor prognosis
- If not treated quickly, patients die within months due to rapid progression
Myelodysplastic Syndromes (MDS) by the numbers
- High-risk MDS is very similar to AML
- Approximately 60–80% of patients experience symptomatic anemia, significantly reducing quality of life
- Often requires repeated blood transfusions
We focus our efforts where the need is great, the science is compelling and actionable, and there is the greatest opportunity to help people live longer, healthier lives.
